Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Faron Pharmaceuticals

2.00 EUR

-2.91 %

5,521 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-2.91 %
-11.11 %
-10.71 %
-21.57 %
-21.26 %
-12.09 %
-56.24 %
-33.99 %
-42.53 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
237.13M EUR
Turnover
798.22K EUR
P/E (adj.) (25e)
-9.07
EV/EBIT (adj.) (25e)
-10.44
P/B (25e)
-27.49
EV/S (25e)
59,000.38
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
2.50 EUR
Updated
24.10.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.10.2025

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.3
2026

Annual report '25

30.3
2026

General meeting '26

26.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Press release3 hours ago

DNB Carnegie Access: Faron Pharmaceuticals: ASH data shows extended survival benefit

Faron Pharmaceuticals
Press release10 hours ago

Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile

Faron Pharmaceuticals
Regulatory press release12/4/2025, 4:00 PM

Faron Pharmaceuticals Ltd: Holding(s) in Company

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release12/3/2025, 2:29 PM

DNB Carnegie Access: Faron Pharmaceuticals: Highlights from DNB Carnegie’s Finnish Healthcare seminar

Faron Pharmaceuticals
Regulatory press release12/3/2025, 10:00 AM

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals
Regulatory press release12/3/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Faron Pharmaceuticals
Regulatory press release12/2/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release12/1/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Appointment of CFO

Faron Pharmaceuticals
Regulatory press release11/27/2025, 7:00 AM

Faron’s Financial Calendar for 2026

Faron Pharmaceuticals
Faron to draw additional 10 MEUR tranche from its convertible bond
Analyst Comment11/25/2025, 9:33 AM by
Antti Luiro

Faron to draw additional 10 MEUR tranche from its convertible bond

No other financing solutions have been announced, and the additional tranche has been part of the company's existing financing reserve, so the release does not come as a particular surprise.

Faron Pharmaceuticals
Regulatory press release11/24/2025, 5:15 PM

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT

Faron Pharmaceuticals
Press release11/4/2025, 11:39 AM

DNB Carnegie Access: Faron Pharmaceuticals: New oral presentation highlights BEXMAB study interest

Faron Pharmaceuticals
Press release11/4/2025, 7:00 AM

Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy

Faron Pharmaceuticals
Press release11/3/2025, 7:00 AM

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment

Faron Pharmaceuticals
Regulatory press release10/28/2025, 7:00 AM

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Faron Pharmaceuticals
Faron: The share price drops offers a chance to buy more
Research10/24/2025, 5:36 AM by
Antti Siltanen

Faron: The share price drops offers a chance to buy more

Faron's share price has fallen, which has improved the risk/reward ratio.

Faron Pharmaceuticals
Faron ESMO 2025
Webcast10/23/2025, 1:00 PM

Faron ESMO 2025

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights.

Faron Pharmaceuticals
Regulatory press release10/21/2025, 1:10 PM

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron's ESMO release complemented the main results reported previously
Analyst Comment10/21/2025, 6:17 AM by
Antti Siltanen

Faron's ESMO release complemented the main results reported previously

On Monday, Faron announced new study results, which were presented at the ESMO conference over the weekend.

Faron Pharmaceuticals
Press release10/20/2025, 8:01 AM

DNB Carnegie Access: Faron Pharmaceuticals: BEXMAB trial shows positive developments at ESMO

Faron Pharmaceuticals
Forum discussions
Commute day to Turku again. This time, Faron’s floor is fully lit. Work is being done, a pleasant sight for the owner. (delete if you want, but I thought it appropriate to provide the information so that the “electricity bills overdue” status from a couple of weeks ago doesn’t remain...
3 hours ago
by Puutaheinää
28
Bono’s post. So, this is about the duration of CR (Complete Response). I wouldn’t be able to doubt its validity on any grounds, my bad. Why wasn’t it in the stock exchange release? Perhaps it wasn’t considered such significant information by anyone other than Bono. The CRO (Contract...
2 hours ago
by Vino Pino
11
Proactive’s normal simplified version (in my opinion, suitable for informing a non-medical audience) Proactiveinvestors UK – 8 Dec 25 Faron drug shows longer survival and strong responses in tough-to-treat blood... Faron Pharmaceuticals Limited (AIM:FARN) has reported fresh data ...
2 hours ago
by Kulkuri
11
From a purely business perspective, there is a point as a function of time where this story shifts from a business case (from successful drug research to quasi-research) to kicking the can down the road and research-driven spinning. Thanks to our experts, this moment in time is likely...
1 hour ago
by Jummijammi2
9
access.dnbcarnegie.com DNB Carnegie Access:
2 hours ago
by marmot76
9
I had already set certain limits for myself earlier, and as a result, I decided today to sell half of my Faron position. I don’t have to waste so much of my life on this stock anymore, as it’s no longer overweight in my portfolio. Let’s see if, with my luck, partner news comes out...
1 hour ago
by Buy and Hold Is Eternal
5
I used to think that if bex had been in Big Pharma’s pipeline, it would have been discarded already after MATINS. But now it’s a different situation, Faron’s practically only asset. The sunk cost fallacy is too strong a force; funding will surely be found from somewhere to continue...
1 hour ago
by Clark kent
5
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.